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 ABSTRACT  
 Background  HLA-DRB1 is associated with rheumatoid 
arthritis (RA). However, it has recently been suggested 
that HLA-DRB1 is only associated with patients with RA 
who have anticitrullinated peptide/protein antibodies 
(ACPA), which are specifi c to RA. 
 Objective  To elucidate whether specifi c HLA-DR alleles 
are associated with ACPA-negative RA development. 
 Methods  HLA-DRB1 typing was carried out in 
368 Japanese ACPA-negative patients with RA and 
1508 healthy volunteers as the fi rst set, followed by 
HLA-DRB1 typing of 501 cases and 500 controls as 
the second set. The HLA-DRB1 allele frequency and 
diplotype frequency were compared in each group, and 
the results of the two studies were combined to detect 
HLA-DRB1 alleles or diplotypes associated with ACPA-
negative RA. 
 Results  HLA-DRB1*12:01 was identifi ed as a novel 
susceptibility allele for ACPA-negative RA (p = 0.000088, 
OR=1.72, 95% CI 1.31 to 2.26). HLA-DRB1*04:05 and 
*14:03 showed moderate associations with ACPA-
negative RA (p = 0.0063, OR=1.26, 95% CI 1.07 to 
1.49 and p = 0.0043, OR=1.81, 95% CI 1.20 to 2.73, 
respectively). The shared epitope was weakly associated 
with ACPA-negative RA, but no dosage effect was 
detected (p = 0.016, OR=1.17, 95% CI 1.03 to 1.34). 
A combination of HLA-DRB1*12:01 and DRB1*09:01 
showed a strong association with susceptibility to 
ACPA-negative RA (p = 0.00013, OR=3.62, 95% CI 1.79 
to 7.30). Homozygosity for HLA-DR8 was signifi cantly 
associated with ACPA-negative RA (p = 0.0070, 
OR=2.16, 95% CI 1.22 to 3.82). It was also found that 
HLA-DRB1*15:02 and *13:02 were protective against 
ACPA-negative RA (p = 0.00010, OR=0.68, 95% CI 0.56 
to 0.83 and p = 0.00059, OR=0.66, 95% CI 0.52 to 0.84, 
respectively). 
 Conclusions  In this large-scale association study 
multiple alleles and diplotypes were found to be 
associated with susceptibility to, or protection against, 
ACPA-negative RA. 
 INTRODUCTION 
 Rheumatoid arthritis (RA) is one of the most 
common causes of chronic arthritis and results 
in severe joint damage and a shorter life span. 1 
Genetic factors have been shown to contribute to 
the onset of RA. 2 Among the genetic  susceptibility 
loci detected to date, HLA-DRB1 has a strong 
impact on the predisposition to RA and has been 
 repeatedly shown to be associated with RA in 
an ethnicity-independent manner. 3 It is widely 
accepted that the shared epitope (SE), a common 
amino acid sequence located from the 70th to the 
74th amino acids of the HLA-DR β chain, explains 
the associations of specifi c HLA-DRB1 alleles with 
RA. 4 Anticitrullinated protein antibodies (ACPA) 
are a highly specifi c marker of RA. 5  6 Recent data 
have shown that the SE is associated with ACPA-
positive RA but not associated or only weakly 
associated with ACPA-negative RA. 7 – 9 Many of 
the non-HLA susceptibility genes for RA detected 
to date, such as  PTPN22 10 and  CTLA4 11 have been 
shown to be associated with ACPA-positive RA 
alone, and no association between these genes and 
ACPA-negative RA has been detected. These fi nd-
ings suggest that ACPA-negative RA is genetically 
distinct from ACPA-positive RA. 
 Among HLA-DRB1 molecules, HLA-DR3 12 and 
HLA-DR13 13 were reported to be associated with 
ACPA-negative RA in populations of European 
descent, but the same results were not obtained 
in a meta-analysis of a large Caucasian cohort. 14 
In Asian populations, there has only been a small 
study which showed that HLA-DRB1*09:01 might 
be associated with ACPA-negative RA, 15 while 
SEs, especially DRB1*04:05, *04:01 and *01:01, 
were associated with RA and ACPA-positive 
RA. 15  16 Thus, no specifi c alleles that convey sus-
ceptibility to, or are protective against, ACPA-
negative RA have been identifi ed in populations 
of European or Asian descent. In this large-scale 
Japanese case–control association study, we show 
that HLA-DRB1*12:01, *14:03 and *04:05 are sus-
ceptibility alleles for ACPA-negative RA and that 
HLA-DRB1*13:02 and *15:02 are protective against 
ACPA-negative RA. We also identifi ed multiple 
diplotypes that convey susceptibility to, or are pro-
tective against, ACPA-negative RA. 
 MATERIALS AND METHODS 
 Study subjects 
 DNA samples were collected at Kyoto University 
Hospital from 184 patients with RA who were 
negative for ACPA, as reported previously, 7 and 
another 184 patients with RA without ACPA were 
recruited at Tokyo Women’s Medical University. 
These two sample groups were used as the fi rst 
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set. Independent DNA samples were collected from 501 
ACPA-negative patients with RA at RIKEN under the support 
of BioBank Japan and were used as the second set. The 501 
cases in the second set are a fraction of 2410 RA cases included 
in another manuscript (K Shimane  et al , unpublished data). All 
patients were Japanese and diagnosed by rheumatologists to ful-
fi l the 1987 American College of Rheumatology revised criteria 
for RA. 17 A fi rst set of control DNA samples were collected from 
1508 healthy control subjects at Aichi Cancer Center Hospital 
and from the DNA banks of the Pharma SNP Consortium, which 
contains DNA samples from healthy Japanese volunteers. 18 
The second set of control DNA samples were collected from 
500 healthy volunteers at the HLA laboratory. This study was 
approved by the local ethical committees at each institution, and 
written informed consent was obtained from all patients. Basic 
information about cases and controls is shown in  table 1 . 
 ACPA detection 
 ACPA were detected with the MESACUP CCP ELISA kit 
(Medical and Biological Laboratories Co, Ltd, Nagoya, Japan) 
according to the manufacturer’s instructions at each institution. 
A cut-off value of 4.5 U/ml was used to assess ACPA positivity. 
 HLA-DRB1 genotyping 
 HLA-DRB1 typing was carried out with the WAKFlow system 
and described in detail elsewhere. 7 In the 184 cases collected at 
Kyoto University and all the controls in the two sets, genotyping 
was performed at the HLA laboratory (Kyoto, Japan), whereas 
it was carried out at RIKEN for all 501 cases in the second set. 
HLA-DRB1 genotyping of the 184 cases collected at Tokyo 
Women’s Medical University was performed by a sequencing-
based typing method using the AlleleSEQR HLA-DRB1 typing 
kit (Abbott, Tokyo, Japan ), and allele assignment was performed 
using the Assign software. 
 The following  HLA-DRB1 alleles were classifi ed as belong-
ing to the SE: DRB1*01:01, *01:02, *04:01, *04:04, *04:05, *04:08, 
*04:10, *04:13, *04:16, *10:01, *13:03, *14:02 and *14:06. 
 Statistical analysis 
 The frequency of each genotype or diplotype among the ACPA-
negative patients with RA was compared with that in the con-
trols using a χ 2 test or Fisher’s exact test. Ninety-fi ve percent 
CIs, p values and ORs were also calculated. The relative risk 
(RR) of ACPA-negative susceptibility induced by homozygos-
ity for each allele was calculated to estimate the dosage effect. 
We performed 1000 permutation tests to confi rm the associa-
tions found for each allele. Logistic regression analysis was used 
to evaluate the effects of alleles by adjusting for the infl uence 
of other alleles. Statistical analysis was performed using the R 
statistic system ( http://www.R-project.org ) or SPSS (version 18). 
The power calculation was performed using an online power 
calculator ( http://pngu.mgh.harvard.edu/~purcell/gpc/ ). 
 RESULTS 
 Genotyping of the fi rst set 
 We performed HLA-DRB1 genotyping in the 368 ACPA-
negative patients with RA and 1508 healthy controls in the fi rst 
set to compare the allele frequency of each genotype between 
the cases and controls ( table 1 ).  Tables 2 and  3 show the main 
results of our association study for single alleles and diplotypes, 
respectively. More detailed results are given in the online sup-
plementary tables 1 and 2. 
 The SE showed a weak association with moderate effect 
(p = 0.039), mainly due to HLA-DRB1*04:05. Among the other 
HLA-DRB1 alleles, HLA-DRB1*14:03, *12:01, and *09:01 resulted 
in moderate to potential susceptibility to ACPA-negative RA 
(p = 0.022, 0.10, and 0.10, respectively). DRB1*13:02, *04:03, 
and *15:02 showed moderate to potentially protective effects 
(p = 0.0072, 0.059, and 0.12, respectively). 
 Replication in the second set and combined analysis 
 We performed HLA-DRB1 genotyping of samples in the second 
set to replicate the results found in the fi rst set, using the DNA 
samples from 501 ACPA-negative patients with RA and 500 sex-
matched healthy controls and combined the results of the two 
association studies. 
 Among the susceptibility alleles found in the fi rst set, HLA-
DRB1*12:01 was confi rmed to display a susceptible association 
(p=0.010 and 0.000088 for the second set and combined study, 
respectively;  table 2 ). The susceptibility tendencies of *04:05 
and *14:03 were replicated in the second set, and these alleles 
showed moderate associations with susceptibility to ACPA-
negative RA in the combined analysis (p = 0.0063 and 0.0043, 
respectively). DRB1*09:01 and *14:05 showed potential suscep-
tibility to ACPA-negative RA in the pooled study (p = 0.062 and 
0.080, respectively). The SE showed a weak association with 
susceptibility to ACPA-negative RA in the combined study 
(p = 0.016), but we could not detect any dosage effect ( table 3 
and  fi gure 1 ). Among the protective alleles detected in the fi rst 
set, the protective effect of DRB1*15:02 was successfully rep-
licated (p = 0.002 and 0.00010 in the second set and combined 
study, respectively;  table 2 ). Although the protective effect of 
DRB1*13:02 was not replicated in the second set, the combined 
analysis showed a signifi cant protective effect (p = 0.00059). The 
protective effect of DRB1*04:03 was confi rmed in the second 
set, and the combined study demonstrated a weak protective 
association (p = 0.038). To exclude the possibility that the asso-
ciations of the susceptibility alleles were induced by the absence 
of protective alleles or vice versa, we applied logistic regression 
analysis. The logistic regression analysis suggested that none 
of the allelic associations—namely, those of HLA-DRB1*12:01, 
*14:03, *04:05, *13:02, and *15:02, depended on the effects of 
other alleles (online supplementary table 3). In addition, the per-
mutation tests confi rmed the associations of these fi ve alleles 
(permutation p<0.0070, data not shown). 
 Next, we analysed the dosage effects of each protective or 
susceptibility allele. DRB1*12:01 showed a potential dosage 
effect, but only two patients were homozygous for DRB1*12:01 
( fi gure 1 ). We could not detect any dosage effects of HLA-
DRB1*04:05 or the SE. No patients were homozygous for *14:03 
 Table 1  Basic information for ACPA-negative patients with RA and 
controls 
Classifi cation ACPA-negative RA Control
Set 1
Number 368 1508
Female (%) 79.7 52.9
Age (mean±SD) 54.7±16.1 46.5±15.3
Set 2
Number 501 500
Female (%) 80.8 80.0
Age (mean±SD) 62.4±12.2 NA
 ACPA, anticitrullinated peptide/protein antibody; NA, not available; RA, rheumatoid 
arthritis. 
13_annrheumdis-2011-200353.indd   2135 10/31/2011   9:07:15 PM
 group.bmj.com on February 9, 2012 - Published by ard.bmj.comDownloaded from 
Extended report
Ann Rheum Dis 2011;70:2134–2139. doi:10.1136/annrheumdis-2011-2003532136
in the cases or controls. Both DRB1*13:02 and *15:02 showed 
potential dosage effects. 
 Diplotype analysis 
 When we analysed the effects of HLA-DRB1 allele diplotypes 
on the predisposition to ACPA-negative RA, we found that a 
combination of DRB1*09:01 and *12:01 demonstrated suscep-
tible effects in both sets (p = 0.025, 0.020 and 0.00013 in the fi rst, 
second and combined study, respectively;  table 3 ). DRB1*08:03 
homozygosity showed a weak susceptible association without 
any dosage effects ( table 3 , s upplementary table 1). Although 
we found no susceptibility effect of DRB1*08:02 homozygos-
ity, the combination of DRB1*08:02 and *08:03 also resulted 
in weak susceptibility (supplementary table 2). When we 
analysed DR8 allele homozygosity, we found that it displayed 
a moderate susceptibility association in the combined analy-
sis (p = 0.0070,  table 3 ). Any combination of two of the three 
susceptibility alleles—namely, HLA-DRB1*12:01, *14:03, and 
*04:05, showed a potentially susceptible effect (supplementary 
table 2). 
 The HLA-DRB1*08:03 and *15:02 diplotype showed the 
strongest protective effect (p = 0.00011,  table 3 ). We found 
that the diplotypes with protective effects (*08:03/*15:02, 
*15:02/*15:02 and *13:02/*15:02) all included HLA-DRB1*15:02 
( table 3 ). 
 DISCUSSION 
 Recent studies have suggested that ACPA-negative RA is a genet-
ically different subset of RA. 7  8 While SE is very strongly asso-
ciated with ACPA-positive RA, it is reported as not associated 
or only weakly associated with ACPA-negative RA. In popula-
tions of European descent, HLA-DR3 and DR13 were reported 
to be susceptibility alleles, 12  13 but a recent meta-analysis of a 
large Caucasian cohort did not fi nd any such association. 14 In 
Japanese subjects, only DRB1*09:01 was reported to be associ-
ated with ACPA-negative RA, using small numbers of patients 
and controls (28 and 265, respectively). 15  16 HLA-DR3 is rare 
in the Japanese population, and we found only one HLA-DR3 
allele in our cohorts. 
 Although genetic factors contribute to the development of 
ACPA-negative RA as much as ACPA-positive RA, 19 little is 
known about the ACPA-negative RA susceptibility alleles of 
HLA and non-HLA genes. 
 Here, we performed a case–control association study using a 
large number of ACPA-negative patients with RA and controls 
and showed that multiple alleles and diplotypes are associated 
 Table 2  Association of the HLA-DRB1 allele with ACPA-negative RA 
 




 † Control, 




 † Control, 




 † Control, 
N (%) p Value OR (95% CI)
Non-SE
Susceptible
*12:01 31 (4.2) 91 (3.0) 0.10 1.41 
(0.93 to 2.14)
62 (6.2) 37 (3.7) 0.010 1.72 
(1.13 to 2.60)
93 (5.4) 128 (3.2) 0.000088 1.72 
(1.31 to 2.26)
*14:03 18 (2.4) 39 (1.3) 0.022 1.91 
(1.09 to 3.36)
23 (2.3) 14 (1.4) 0.14 1.65 
(0.85 to 3.23)
41 (2.4) 53 (1.3) 0.0043 1.81 
(1.20 to 2.73)
*09:01 123 (16.7) 432 (14.3) 0.10 1.20 
(0.96 to 1.49)
164 (16.4) 154 (15.4) 0.55 1.08 
(0.85 to 1.37)
287 (16.5) 586 (14.6) 0.062 1.16 
(0.99 to 1.35)
*14:05 19 (2.6) 63 (2.1) 0.41 1.24 
(0.74 to 2.09)
29 (2.9) 18 (1.8) 0.11 1.63 
(0.9 to 2.95)
48 (2.8) 81 (2.0) 0.080 1.38 
(0.96 to 1.98)
Protective
*15:02 75 (10.2) 369 (12.2) 0.12 0.81 
(0.63 to 1.06)
73 (7.3) 113 (11.3) 0.0020 0.62 
(0.45 to 0.84)
148 (8.5) 482 (12.0) 0.00010 0.68 
(0.56 to 0.83)
*13:02 44 (6.0) 273 (9.1) 0.0072 0.64 
(0.46 to 0.89)
52 (5.2) 52 (5.2) 0.99 1.00 
(0.67 to 1.48)
96 (5.5) 325 (8.1) 0.00059 0.66 
(0.52 to 0.84)
*04:03 14 (1.9) 97 (3.2) 0.059 0.58 
(0.33 to 1.03)
23 (2.3) 28 (2.8) 0.47 0.82 
(0.47 to 1.43)
37 (2.1) 125 (3.1) 0.038 0.68 
(0.47 to 0.98)
SE
*04:05 103 (14.0) 340 (11.3) 0.040 1.28 
(1.01 to 1.62)
145 (14.5) 129 (12.9) 0.31 1.14 
(0.89 to 1.47)
248 (14.3) 469 (11.7) 0.0063 1.26 
(1.07 to 1.49)
*14:06 16 (2.2) 37 (1.2) 0.051 1.79 
(0.99 to 3.23)
14 (1.4) 9 (0.9) 0.30 1.56 
(0.67 to 3.62)
30 (1.7) 46 (1.1) 0.076 1.52(0.95 to 
2.41)
*10:01 8 (1.9) 13 (0.4) 0.032 2.54 
(1.05 to 6.15)
6 (0.6) 5 (0.5) 0.76 1.20 
(0.36 to 3.94)
14 (0.8) 18 (0.4) 0.094 1.80 
(0.90 to 3.63)
*04:04 4 (0.5) 6 (0.2) 0.10 2.74 
(0.77 to 9.74)
3 (0.3) 2 (0.2) 0.66 1.50 
(0.25 to 8.99)
7 (0.4) 8 (0.2) 0.16 2.03 
(0.73 to 5.60)
*01:01 43 (5.8) 183 (6.1) 0.82 0.96 
(0.68 to 1.35)
50 (5.0) 64 (6.4) 0.17 0.77 
(0.52 to 1.12)
93 (5.4) 247 (6.2) 0.24 0.86 
(0.67 to 1.10)
*04:01 12 (1.6) 35 (1.2) 0.30 1.41 
(0.73 to 2.73)
10 (1.0) 10 (1.0) 1.0 1.00 
(0.41 to 2.41)
22 (1.3) 45 (1.1) 0.64 1.13 
(0.68 to 1.89)
*04:10 6 (0.8) 63 (2.1) 0.021 0.39 
(0.17 to 0.89)
25 (2.5) 14 (1.4) 0.076 1.80 
(0.93 to 3.49)
31 (1.8) 77 (1.9) 0.73 0.93 
(0.61 to 1.41)
All SE 192 (26.1) 677 (22.4) 0.036 1.22 
(1.01 to 1.47)
253 (25.3) 233 (23.3) 0.31 1.11 
(0.91 to 1.36)
445 (25.6) 910 (22.7) 0.016 1.17 
(1.03 to 1.34)
 Allele number and the frequency of each HLA-DRB1 allele in ACPA-negative patients with RA (n=368 and allele number=736 in the 1st set and n=501 and allele number=1002 in the 
2nd set) and healthy controls (n=1508 and allele number=3016 in the 1st set and n=500 and allele number=1000 in the 2nd set) as well as the p value and OR of each allele for the 
development of ACPA-negative RA are shown. p Values were calculated using Fisher’s exact test or the χ 2 test. 
 † Number of alleles (allele frequency). 
 ACPA, anticitrullinated peptide/protein antibody; SE, shared epitope; RA, rheumatoid arthritis. 
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with ACPA-negative RA in Japanese people. Although the con-
trols in the fi rst set had different age and sex ratio values from 
those of the patients and we could not obtain age data for the 
500 controls in the second set, the effects of the above-men-
tioned difference and lack of data on our results were considered 
to be limited. The HLA locus is located on chromosome 6 and 
is not affected by sex or age. Indeed, regression analysis did not 
signifi cantly alter our association results (data not shown). 
 Our study showed that HLA-DRB1*12:01 is strongly associ-
ated with ACPA-negative RA and that HLA-DRB1*14:03 and 
HLA-DRB1*04:05 in SE are moderately associated with ACPA-
negative RA in Japanese people. All three susceptibility alleles 
showed susceptibility associations with ACPA-negative RA 
when found in combination with one of the other two alleles. 
Our data also suggested a dosage effect of HLA-DRB1*12:01, 
while no dosage effect of HLA-DRB1*04:05 was detected, with 
decreased OR of DRB1*04:05 in homozygotes compared with 
heterozygous patients. In addition, we showed that the HLA-
DRB1*09:01 and HLADRB1*12:01 diplotype and HLA-DR8 
homozygosity are strong susceptibility combinations for ACPA-
negative RA. We also determined HLA-DRB1*13:02 and *15:02 
as protective alleles against ACPA-negative RA with a potential 
dosage effect. The combination of DRB1*08:03 and *15:02 had 
a strong protective effect in our study. Using logistic regression 
analysis, we confi rmed that the effects of these susceptibility 
and protective alleles do not depend on each other (supple-
mentary table 3). Although we searched for common amino 
acid sequences among the susceptibility alleles, we could not 
detect any meaningful sequences common to HLA-DRB1*12:01, 
*14:03, and/or *04:05. We also failed to detect a common amino 
acid sequence among the protective alleles HLA-DRB1*15:02 
and *13:02. 
 Although the association of SE with ACPA-negative RA can-
not be concluded, our large-scale study showed that it is weakly 
associated with ACPA-negative RA. As we observed a lower 
OR of the SE in homozygotes than in heterozygous patients, 
confi rmation of this association in other studies are needed. We 
consider that the SE is associated with ACPA-negative RA but 
has a much weaker effect than in ACPA-positive RA. Both the  Ta
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 Figure 1  Suggestive dosage effect of associated alleles on 
anticitrullinated peptide/protein antibody (ACPA)-negative rheumatoid 
arthritis susceptibility. The OR for each genotype is shown. Different 
colours indicate the number of copies of each allele. The numbers 
of homozygotes of *12:01, *14:05, *15:02, and *13:02 in cases are 
limited (2, 2, 3 and 3, respectively). Since no patients in this study 
were homozygous for DRB1*14:03, only the result for *14:05 is shown 
in this fi gure. SE in the fi gure includes DRB1*04:05, which is shown 
separately. 
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relatively small effect of SE on ACPA-negative RA and the small 
number of cases in previous reports might have resulted in non-
signifi cant p values for such tendencies. 
 HLA-DRB1*12:01, which was found to be associated with 
ACPA-negative RA susceptibility in our study, was reported to be 
associated with type 1 diabetes mellitus (T1D) in Latin America, 
but no similar association has been reported in Japan. 20  21 While 
a Japanese study showed RA with the anti-glucose-6-phosphate 
isomerase antibody is associated with HLA-DRB1*12:01, 22 no 
large-scale studies have reported an association between HLA-
DRB1*12:01 and RA. As RA shares susceptibility genes with 
T1D such as  PTPN22 , 23 the determination of HLA-DRB1*12:01 
as a potential common risk allele for both T1D and ACPA-
negative RA is interesting. Although HLA-DRB1*12:01 showed 
a possible dosage effect, further confi rmation is necessary as 
only two homozygous patients were among the cases. The 
allele frequency of HLA-DRB1*12:01 in a European population 
is 1–4%, 24 and so far there are no reports showing an association 
with ACPA-negative RA. 14 HLA-DRB1*12:02, the other allele of 
HLA-DR12, showed no association with ACPA-negative RA. 
 HLA-DRB1*14:03 was reported to be associated with Grave’s 
disease in Japanese patients, 25 but its role in RA is unknown. 
Although our samples did not contain any patients who were 
homozygous for the allele owing to its low allele frequency, it 
showed a moderate association with ACPA-negative RA sus-
ceptibility. Among the other non-SE DR14 alleles, DRB1*14:05 
displayed a tendency towards ACPA-negative RA susceptibility, 
while *14:01 and *14:07 did not. In total, DR14 alleles, including 
*14:06 in SE, showed moderate susceptibility effects on ACPA-
negative RA (supplementary table 1). 
 Although one European study suggested that HLA-DR15 has a 
protective effect against ACPA-negative RA, its effect on ACPA-
negative RA has not been fully examined. 13 We showed that 
HLA-DR15 has strong protective effect against ACPA-negative 
RA and a possible dosage effect. HLA-DRB1*15:02 is reported to 
be associated with Japanese T1D in a protective manner. 21 
 Among HLA-DR13 alleles, HLADRB1*13:02 was reported 
to be protective against ACPA-positive RA. 26  27 Its protective 
effect was also reported in Japanese patients with RA. 16 Its 
effect on ACPA-negative RA has not been established. 13  14 Our 
study suggested that HLA-DRB1*13:02 has a protective effect 
against ACPA-negative RA. As the second set in our study 
did not show any differences in allele frequency between the 
patients and controls, further validation of our fi ndings is neces-
sary. HLA-DRB1*13:01, a major component of DR13 in popula-
tions of European descent, had no effect in our study, where we 
included DRB1*13:01 in eight alleles in cases and 23 alleles in 
controls (p=0.59). 
 HLA-DR8 has also been reported to be associated with some 
arthropathic autoimmune diseases, such as juvenile idiopathic 
arthritis 28 and psoriatic arthritis 29 in European subjects. The 
associations indicate that these arthropathies share common 
pathological mechanisms. Interestingly, the combination of 
DR8 and DR15 had a strong protective effect against ACPA-
negative RA. Considering that DR8 did not show susceptibility 
association as a single allele, it seems to induce ACPA-negative 
RA susceptibility in a recessive manner. Among the DR8 alleles, 
DRB1*08:03 appeared to have a strong effect on ACPA-negative 
RA susceptibility. 
 Although we did not detect a dosage effect of HLA-
DRB1*04:03, it showed a potentially protective effect against 
ACPA-negative RA in the combined study. Further studies are 
necessary to confi rm the association. 
 As DRB1*09:01 has been shown to be associated with a 
decreased ACPA titre in ACPA-positive RA, 30 it is likely to be 
associated with ACPA-negative RA. While DRB1*09:01 showed 
a potential susceptibility association (p=0.062), the combination 
of DRB1*09:01 and *12:01 showed strong susceptibility asso-
ciation (p=0.00013). DRB1*09:01 also showed a possible dosage 
effect. From this viewpoint, we consider that DRB1*09:01 has 
a potential susceptibility effect on ACPA-negative RA. Owing 
to the relatively high allele frequency of DRB1*09:01, another 
independent association study or appropriate classifi cation of 
ACPA-negative RA could produce signifi cant results. 
 In addition to the different associations of the SE with ACPA-
negative RA and ACPA-positive RA, we found multiple alleles 
associated with ACPA-negative RA that are not shared by 
ACPA-positive RA. These showed that ACPA-negative RA is a 
distinct subset of RA. Moreover, when we focused on ACPA-
negative erosive RA to exclude the possibility of our results 
being affected by non-RA arthritic diseases, the effects of all the 
following alleles were maintained: *12:01, *14:03, *04:05, *13:02 
and *15:02 (data not shown). 
 This is the fi rst large-scale association study involving 
Japanese ACPA-negative patients with RA and the detection of 
multiple alleles and diplotypes associated with susceptibility to, 
or protection against, ACPA-negative RA. To evaluate whether 
our cohort had suffi cient power to detect HLA-DRB1 genotype 
associations, we applied a risk allele with 5% frequency in the 
general population (see ‘Materials and methods’). Our power 
calculation showed that this study had power values of 81% 
for fi nding genotype associations with an OR of 1.4 at the 0.05 
signifi cance level. When we set the OR to 1.2, our study had 
power values of 31%. These results suggest that our study has 
suffi cient power to detect associated alleles that are present in 
relatively high frequencies (such as 5%) and a moderate OR of 
1.4. On the contrary, our study has insuffi cient power to detect 
associations involving a weak OR such as 1.2. There is a possibil-
ity that ACPA-negative RA is associated with more HLA-DRB1 
alleles or diplotypes that display a low allele frequency and/or 
a low OR. Further studies using ACPA-negative RA samples in 
Japan are necessary to fi nd such associations. 
 While association studies using ACPA-negative patients with 
RA of European descent only found a few weak associations 
and none of them were subsequently replicated, our study 
successfully determined multiple alleles with relatively strong 
effects on ACPA-negative RA. From this viewpoint, we suppose 
that Japanese ACPA-negative patients with RA have a relatively 
similar genetic background compared to European patients. 
Population stratifi cation within European population may also 
be assumed. Nevertheless, the validation of our results in Asian 
countries is necessary, and large-scale genome-wide association 
studies of ACPA-negative RA are also required to elucidate the 
pathogenesis of ACPA-negative RA. 
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